Company profile

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies such as T cell receptor-modified T cells (TCR‑Ts) or dendritic cell (DC) vaccines to treat cancer in fields of high medical need. The first product candidates are in clinical development.

Company Strategy

Medigene’s strategy is to develop its own therapies towards clinical proof-of-concept with the ultimate aim of advancing its technologies into development against solid cancers. In addition, the Company offers selected partners the opportunity to discover and develop additional therapies on the basis of its technological platforms.

Short Profile

  • Focus on T-cell-directed immunotherapies
  • TCR-T therapy MDG1011 in patients with acute myeloid leukemia (AML) or myelodisplastic syndrome (MDS) in clinical Phase I/II trial
  • Completed clinical Phase I/II trial of DC vaccine in patients with AML
  • Roughly 80 employees with expertise in immunotherapy and pharmaceutical development
  • Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California
  • Listed on Frankfurt Stock Exchange: MDG1; ISIN DE000A1X3W00

Company History

1994Medigene founded as Munich Gene Center spin-off
2000Medigene IPO listed on the Frankfurt Stock Exchange
2001Medigene acquired US biotechnology company NeuroVir, Inc.
2004Medigene acquired products and technology of Munich Biotech AG
2004Medigene received first regulatory approval for cancer drug Eligard® in Germany
2006Medigene acquired British biotechnology company Avidex Limited
2006Medigene’s product Veregen® became the first FDA-approved biopharmaceutical of a German biotech company in the USA
2012-14Strategic repositioning through sale of Eligard®, EndoTAG® and RhuDex®
2014Focus on immuno-oncology by strategic acquisition of Trianta Immunotherapies GmbH (renamed Medigene Immunotherapies GmbH)
2015Start of Phase I/II clinical trial with DC vaccine (FDC101) to treat AML
2015Amgen acquires Medigene spin-off Catherex
2016Start of Phase II part of the clinical trial with DC vaccine (FDC101)
2016bluebird bio and Medigene establish strategic T cell receptor alliance in cancer immunotherapy
2017U.S.-rights for Veregen® are disposed
2018Expansion of the bluebird bio partnership
2018Start of the Phase I/II study of MDG1011 in AML and MDS
2019Roivant and Sinovant launch Cytovant Sciences in partnership with Medigene to develop cellular therapies in Asia
2019Sale of  remaining rights and inventories of Veregen® 
2020Publication of topline data of the DC vaccine trial (FDC101)
2021Publication of topline data of the Phase I/II study of MDG1011 in AML and MDS
2022Comprehensive research and development partnership with BioNTech